Trial Profile
A phase Ib/IIa trial of multiple doses of MNGX-100 for the treatment of naturally-occurring or surgically-induced menopausal syndrome.
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 09 May 2018
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Menopausal syndrome
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors MenoGeniX
- 03 May 2018 According to a MenoGeniX media release, National Institutes of Health (NIH) has awarded the fund to support this study.
- 12 Mar 2016 According to the company website, this phase II trial of MNGX-100 for the treatment of naturally-occurring or surgically-induced menopausal syndrome is anticipated to start in 2016.
- 12 Mar 2016 New trial record